Digital health investment is showing signs of recovery—but with a clear shift in how capital is being deployed. A recent report covered by Fierce Healthcare, based on data from Rock Health, found that start-ups raised $4 billion in Q1 2026, making it the strongest first quarter since the pandemic-era peak and a $1 billion increase year over year.
What’s driving this growth, however, isn’t broad-based momentum—it’s concentration at the top. Nearly 60% of all funding went to just 12 “megadeals” (rounds of $100M+), signalling a market where investors are placing bigger bets on fewer, more mature companies. This has created a “haves vs. have-nots” dynamic, where well-positioned start-ups continue to attract large rounds while others struggle to secure funding.
Another defining trend is the normalization of AI. Rather than being a differentiator, AI is now table stakes across digital health, making it harder to distinguish between companies based on technology alone. As a result, investors are increasingly backing start-ups that can demonstrate real-world traction—particularly those embedded in clinical workflows, data infrastructure, and operational efficiency.
At the same time, deal sizes are growing, with the average round reaching $36.7 million, the highest level since 2021. M&A activity is also ticking up, but the IPO market remains cautious, with many companies delaying exits amid economic uncertainty.
The takeaway: digital health funding is rebounding, but the market is becoming more selective and mature. Capital is flowing to fewer companies with stronger proof points, signalling a shift from rapid experimentation to disciplined growth and scalable business models.
Read the full report on Fierce Healthcare.
